CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Pelthos Q3 Zelsuvmi revenue jumps 114%, net loss narrows

By Reuters News


Overview

  • US dermatology drugmaker's Q3 Zelsuvmi revenue rose 114% yr/yr to $15.2 mln

  • Net loss for Q3 narrowed to $7.9 mln from $16.2 mln a year ago

  • Company to merge with Castle Creek to form diversified biotech


Outlook

  • Pelthos expects continued growth for Zelsuvmi as coverage and access expand

  • Company targets Xepi launch in Q1 2027 and Xeglyze launch in Q3 2027

  • Pelthos expects Castle Creek merger to close by end of Q1 2027


Result Drivers

  • ZELSUVMI UTILIZATION - Co said Q3 Zelsuvmi revenue growth was driven by increased use by healthcare providers and expanded access

  • EXPANDED COVERAGE - Co cited increased formulary coverage, reaching 127 mln commercially covered lives and strong Medicaid coverage, as supporting Zelsuvmi access

  • COST OF GOODS SOLD - Co reported a reduction in cost of goods sold, citing lower inventory-related charges compared to prior periods


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$7.9 mln

Q3 Adjusted EBITDA

-$5.6 mln

Q3 Operating Income

-$9.69 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Pelthos Therapeutics Inc is $50.00, about 432.5% above its November 11 closing price of $9.39


Reuters Recommended Reads

  • Nov 9 - Ocular Therapeutix Q3 loss widens as product revenue drops, costs rise

  • Nov 10 - Kura Oncology's Q3 KOMZIFTI revenue rises 53% sequentially

  • Nov 10 - Scholar Rock posts first product revenue after ISEMBYLD launch


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.